- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06735378
Exercise Preconditioning to Protect Against Dialysis-induced Cardiac Injury
Exercise Preconditioning to Protect Against Dialysis-induced Cardiac Injury in Hemodialysis Patients: a Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jarrin Penny, PhD, RN, CNeph (C)
- Phone Number: 58765 519-685-8500
- Email: jarrin.penny@lhsc.on.ca
Study Contact Backup
- Name: Kathy Koyle
- Phone Number: 56214 519-685-8500
- Email: kathleen.koyle@lhsc.on.ca
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Recruiting
- London Health Sciences Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- must be on chronic hemodialysis for at least 3 months
- age 18 years or older
- willing and able to provide informed consent
- assessed to be safe and able to exercise by unit HD Nephrologist
Exclusion Criteria:
- regular vigorous exercise outside of hemodialysis
- over 79 years of age
- intradialytic exercise < 3 months
- poor echogenicity
- acute coronary syndrome in the past 3 months
- unstable arrhythmia/angina
- shortness of breath at rest or with minimal activity
- symptomatic hypoglycemia (>2x/week in the week prior to enrolment)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Randomization Order 1
Participants will be randomized into one of the two groups indicating the order in which they will receive the exercise intervention. Randomization Order 1 will receive the exercise treatment on the first day of the first week of the study. The other three days without exercise will consist of standard dialysis sessions with study procedures. |
The impact of interdialytic exercise on cardio protection during HD has never been studied.
This approach may enhance cardiovascular benefits and overall physical fitness, thereby contributing to better health outcomes in individuals undergoing HD.
|
|
Experimental: Randomization Order 2
Participants will be randomized into one of the two groups indicating the order in which they will receive the exercise intervention. Randomization Order 2 will receive the exercise treatment on the first day of the fourth week of the study. The other three days without exercise will consist of standard dialysis sessions with study procedures. |
The impact of interdialytic exercise on cardio protection during HD has never been studied.
This approach may enhance cardiovascular benefits and overall physical fitness, thereby contributing to better health outcomes in individuals undergoing HD.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the number of left ventricular segments undergoing a greater than 20% reduction in longitudinal strain as detected by echocardiogram
Time Frame: week 1 to week 4
|
An echocardiogram will be completed pre-hemodialysis (HD) treatment and at peak hemodynamic stress (30 min before the end of HD treatment) at each of the four study sessions.
Images will be captured in the left lateral position and standard apical 4, 2, and 3 chamber views will be recorded for analysis using automated speckle-tracking software (EchoPac, GE Healthcare)
|
week 1 to week 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluate potential targets of preconditioning by exercise-induced cardio protection by focusing on hemodynamics (Blood Pressure)
Time Frame: week 1 to week 4
|
Systolic blood pressure (SBP), Diastolic blood pressure (DBP) and mean arterial pressure (MAP) will be measured using an automated blood pressure monitor integrated into the dialysis machine.
Values will be monitored throughout each study.
|
week 1 to week 4
|
|
Evaluate potential targets of preconditioning by exercise-induced cardio protection focusing on hemodynamics (CV Insight Monitoring),
Time Frame: week 1 to week 4
|
The CV Insight contact device is a non-invasive continuous hemodynamic real time monitoring system used to assess cardiovascular and respiratory status using percutaneous photoplethysmography.
The device will be attached to the right of the patient's forehead midline, approximately 2.5 cm above the level of the nose pre-dialysis and will remain intact until the patient is disconnected from the dialysis machine at each study session.
Once attached, baseline recording will be obtained, and hemodynamic data will be continuously captured.
|
week 1 to week 4
|
|
Evaluate potential targets of preconditioning by exercise-induced cardioprotection, focusing on hemodynamics (Finapres)
Time Frame: week 1 to week 4
|
The Finometer utilizes a finger-cuff method to detect beat-to-beat changes in digital arterial diameter using an infrared photoplethysmography.
The time-averaged data is subsequently downloaded to a computer-based analysis program for analysis.
The finger-cuff will be placed on the participant's index finger at each study visit and will remain in place throughout the entire study visit
|
week 1 to week 4
|
|
Evaluate potential targets of preconditioning by exercise-induced cardio protection, focusing on blood markers
Time Frame: week 1 to week 4
|
Blood samples will be collected from the participants dialysis access.
Before HD and at peak-stress of each study session, will be collected for biochemistry, proteomic analysis and translational approach.
|
week 1 to week 4
|
|
Evaluate potential targets of preconditioning by exercise-induced cardio protection, focusing on erythrocyte deformability
Time Frame: week 1 to week 4
|
Blood samples will be collected from the participants dialysis access.
Before HD and at peak-stress of each study session for analysis of erythrocyte deformability which indicates microcirculation efficiency
|
week 1 to week 4
|
|
Evaluate potential targets of preconditioning by exercise-induced cardio protection, focusing on endothelial function
Time Frame: week 1 to week 4
|
Endothelial function is assessed by measuring the dilatory response of the brachial artery to increased blood flow generated by reactive hyperemia in the downstream forearm.
At each study session participants are placed in the supine position and the brachial artery of the non-dominant arm, or the non-distended arm is scanned in longitudinal section using a 12 MHz linear transducer connected to a Vivid Q echograph (GE, USA) supplemented by an electrocardiogram (ECG).
|
week 1 to week 4
|
|
Evaluate potential targets of preconditioning by exercise-induced cardioprotection, focusing on proteomic analysis.
Time Frame: week 1 to week 4
|
Proteomic alterations in plasma are important in the inflammatory response to ischemia-reperfusion (IR) injury.
Blood Samples (plasma) will be collected pre and peak dialysis at each study session for the analysis of changes induced by exercise preconditioning, with the aim of identifying new potential targets for cardio protection.
|
week 1 to week 4
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christopher McIntyre, London Health Sciences Centre Research Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 15393
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemodialysis
-
National Taiwan University HospitalCompletedHemodialysis Complication | Hemodialysis-Induced SymptomTaiwan
-
University Hospital, GhentEnrolling by invitationPediatric | Efficiency | Hemodialysis Treatment | Hemodialysis PatientBelgium
-
Khon Kaen UniversityCompletedHemodialysis | Hemodialysis Treatment | Dialysis AdequacyThailand
-
Vantive Health LLCBaxter Healthcare Corporation; Gambro Renal Products, Inc.Completed
-
Osaka UniversityCompleted
-
Chinese PLA General HospitalWithdrawn
-
University of HyogoCompleted
-
DVX, LLCNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Renal...Completed
-
Dong-A UniversityCompletedHemodialysisKorea, Republic of
Clinical Trials on Intradialytic Cycling
-
University of ManitobaCanadian Institutes of Health Research (CIHR)Completed
-
London Health Sciences Centre Research Institute...Active, not recruiting
-
Universitas Muhammadiyah SurakartaCompletedHemodialysis | Chronic Kidney Disease | End-stage Renal Disease (ESRD)Indonesia
-
University of ManitobaUniversity of Alberta; University of CalgaryCompletedIntradialytic Hypotension | Hemodialysis-Induced SymptomsCanada
-
University of CalgaryCompletedEnd Stage Kidney DiseaseCanada
-
Pardis Specialized Wellness InstituteCompletedHemodialysis | End Stage Renal Disease | Kidney Disease, ChronicIran, Islamic Republic of
-
Kafkas UniversityCompletedHemodialysis | Muscular CrampsTurkey
-
Chulalongkorn UniversityCompletedSedentary Lifestyle | Hemodialysis | End Stage Renal DiseaseThailand
-
University of MichiganRenal Research InstituteCompletedKidney Failure, ChronicUnited States
-
Istanbul Medipol University HospitalMedipol UniversityRecruiting